Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 42

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 42
---
 our Common Stock (such rights, the “ Purchase Rights”), then each holder of a common warrant will be entitled to participate in the offering of Purchase Rights as if the holder of a common warrant were a holder of our Common Stock. The amount of Purchase Rights that a holder of a common warrant could acquire would be the amount of Purchase Rights the holder could have acquired if the holder of a common warrant had held the number of shares of Common Stock acquirable upon complete exercise of their common warrant immediately before the date on which a record date is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of our Common Stock is determined for the grant, issue or sale of such Purchase Rights. The number of shares issuable to common warrant holders in excess of the Beneficial Ownership Limitation will be held in abeyance until such time as the issuance would be in compliance with such limitation.

| 20 |

<div align='center'>PLAN OF DISTRIBUTION</div>

Brookline has agreed to act as our Placement Agent in connection with this offering subject to the terms and conditions of the placement agency agreement dated , 2025. The placement agency agreement provides that the Placement Agent obligations are subject to conditions contained in the placement agency agreement. The Placement Agent is not purchasing or selling any such securities, nor is it required to arrange for the purchase and sale of any specific number or dollar amount of such securities, other than to use its “reasonable best efforts” to arrange for the sale of such securities by us. Therefore, we may not sell all of the shares of Common Stock, pre-funded warrants and common warrants being offered. The terms of this offering are subject to market conditions and negotiations between us, the Placement Agent and prospective investors. The securities will be offered at a fixed price and are expected to be issued in a single closing. The offering will terminate on May 30, 2025, unless (i) the closing occurs prior thereto or (ii) we decide to terminate the offering prior thereto (which we may do at any time in our discretion), except that the shares of Common Stock underlying the warrants and shares of Common Stock underlying the pre-funded warrants will be offered on a continuous basis pursuant to Rule 415 under the Securities Act. We will enter into a securities purchase agreement directly with certain investors, at the investor’s option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on